Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch. Eyeballs or optical delusion?

This article was originally published in Scrip

Executive Summary

The recent acquisition of the shares of Alcon that Novartis didn’t own for about $13 billion might have reinforced investors’ appetite for eye care-related pharmaceuticals (, 15 Dec 2010). However, Novartis’ consolidation of Alcon appeared more of a move to wholly own a separate business unit complete with sales force, a dominant position in soup-to-nuts eye care and sales of $6.5bn, than a focus on a particular new drug. On the other hand, Sanofi’s acquisition of the private company Fovea Pharmaceuticals SA (, 1 Oct 2009) marked a rare big pharmaceutical foray for an ophthalmology pipeline.


Related Content

Stockwatch: A Biopharma Nativity Play

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts